It appears there's interest in recent news concerning CVM (Cel-Sci Corporation). Looking at recent filings and news, the primary focus for the company in 2025 involved capital raising activities to support its clinical development.
Key developments include:
- Public Offerings: CEL-SCI conducted two public offerings in 2025. In May 2025, the company priced an offering of 2,000,000 shares at $2.50 per share, aiming to raise $5 million in gross proceeds.1 A subsequent best-efforts offering was priced in August 2025, selling 1,111,200 shares at $9.00 per share, expected to generate approximately $10 million in gross proceeds.2 The stated purpose for both offerings was to fund the continued development of Multikine, for general corporate purposes, and working capital.1
- SEC Filings: The company filed a 10-Q in May 20253 and its annual 10-K report in December 2025.4 These filings would provide detailed financial and operational updates, including the impact of the capital raises.
- Analyst Sentiment: As of July 16, 2025, Fintel data indicated an average one-year price target for CVM of $306, reflecting analyst sentiment.5
These capital raises are significant events for a clinical-stage biotechnology company like Cel-Sci, as they provide the necessary funding for ongoing research and development, particularly for its lead investigational drug, Multikine. Investors would typically monitor how these funds are deployed and the progress of clinical trials.
